-
Tropisetron Hydrochloride: Assay Workflows
2026-08-17
Tropisetron Hydrochloride supports paired studies of 5-HT3 receptor blockade, α7-nicotinic receptor signaling, and renal organic-cation transport. This workflow-focused guide shows how to separate receptor pharmacology from OCT2/MATE1 transporter effects and troubleshoot common assay failures.
-
Cancer Drug Responses: Growth Arrest vs Cell Death
2026-08-16
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug activity. Its central practical contribution is a time-aware framework for separating proliferative arrest from actual cell killing, improving interpretation of in vitro drug-response experiments.
-
LY2228820: p38 MAP kinase inhibitor workflows
2026-08-15
LY2228820 enables targeted interrogation of p38α/β signaling across inflammation, oncology, cytokine, and angiogenesis assays. This workflow-focused guide connects phospho-MK2 measurements with combination cytotoxicity, apoptosis assay design, solubility control, and a newer phosphatase-aware interpretation of p38 inhibition.
-
Anti-Diabetic Drugs and Fracture Risk: Network Evidence
2026-08-14
Zhang et al. used a systematic review and network meta-analysis to compare fracture outcomes across multiple anti-diabetic therapies in people with type 2 diabetes. The findings support drug-specific rather than class-wide interpretation, while highlighting the need to distinguish statistical signals from causal skeletal effects.
-
Procainamide Hydrochloride: From Channel to Assay
2026-08-14
Procainamide Hydrochloride is more than a cardiac sodium channel blocker: it is a useful probe for linking ion-channel pharmacology with platinum disposition and tissue injury. This article translates the key rat findings into practical assay-design decisions while defining the compound’s translational limits.
-
Tau Ser356, NUAK Inhibition, and Alzheimer’s Pathology
2026-08-13
Taylor et al. characterize tau phosphorylated at serine 356 as a pathology-associated species that increases with Alzheimer’s disease progression and is frequently present in neurofibrillary tangles. Using array tomography and complementary mouse and human brain-slice models, the study shows that NUAK inhibition with WZ4003 lowers p-tau Ser356 in live human tissue, while mouse cultures display broader and potentially less selective protein loss.
-
(S)-Mephenytoin: CYP2C19 Organoid Assays
2026-08-13
(S)-Mephenytoin provides a mechanistically defined CYP2C19 substrate for measuring oxidative drug metabolism in recombinant systems, microsomes, and human intestinal models. When paired with hiPSC-derived intestinal organoids, it can help connect enzyme activity with epithelial context, first-pass metabolism, and pharmacokinetic studies.
-
Staurosporine Beyond Apoptosis: A Translational Lens
2026-08-12
Staurosporine is more than a classical apoptosis trigger: its broad kinase activity can expose how treatment stress reshapes tumor-cell states. This thought-leadership guide connects kinase inhibition, VEGF signaling, near-death survival, and prometastatic biology to practical experimental strategy in cancer research.
-
Mianserin HCl–DM-β-CD: Toxicity Findings
2026-08-12
The reference study shows that heptakis (2,6-di-O-methyl)-β-cyclodextrin forms inclusion complexes with mianserin hydrochloride but does not protect cells from drug-associated toxicity. Instead, the complex produced lower B14-cell viability than mianserin alone, demonstrating why supramolecular formulation effects must be measured rather than assumed.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-08-11
The reference study establishes a more accessible direct 3D culture strategy for generating human induced pluripotent stem cell-derived intestinal organoids with long-term expansion, differentiation, and cryopreservation capacity. Their epithelial derivatives display intestinal transporter and cytochrome P450 activities, supporting a human-relevant platform for investigating absorption and metabolism during pharmacokinetic studies.
-
From Barrier Biology to Better Biotin Imaging
2026-08-11
Biohybrid microrobots are opening new routes through complex tumor barriers, but translational progress depends on proving where these systems go and what they engage. This article connects the mechanistic findings of a recent Euglena gracilis microrobot study with practical use of Streptavidin-Cy3 as a modular fluorescent readout for biotinylated targets.
-
Phalloidin B7678: F-Actin Workflow Guide
2026-08-10
Phalloidin (SKU B7678) is a cyclic heptapeptide toxin that binds filamentous actin and supports cytoskeleton visualization in fixed or permeabilized samples. This guide outlines practical handling and assay setup while emphasizing that it is not appropriate for live-cell imaging or experiments requiring reversible actin remodeling.
-
Neuromedin S (rat): Practical Protocol Guide
2026-08-09
Neuromedin S (rat) provides a chemically defined rat peptide agonist for controlled neuromedin U receptor activation when ligand identity and handling need standardization. It is intended for research GPCR/G protein assays and related laboratory workflows after local validation, not for diagnostic, therapeutic, or medical use.
-
Liproxstatin-1 as a Ferroptosis Assay Probe
2026-08-08
Liproxstatin-1 is a selective ferroptosis inhibitor that helps distinguish lipid-peroxidation-driven death from nonspecific oxidative injury. This article explains how to use it as a causal assay probe, including careful interpretation of emerging fungal ferroptosis data.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-08-07
Saito and colleagues developed a streamlined direct 3D culture strategy for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. After conversion to 2D intestinal epithelial monolayers, the organoids produced mature intestinal cell types with measurable transporter and CYP3A metabolic activities, supporting more human-relevant pharmacokinetic studies.